Skip Navigation LinksHome > October 2012 - Volume 120 - Issue 4 > Progestogens for Preterm Birth Prevention: A Systematic Revi...
Obstetrics & Gynecology:
doi: 10.1097/AOG.0b013e3182699a15
Reviews

Progestogens for Preterm Birth Prevention: A Systematic Review and Meta-Analysis

Likis, Frances E. DrPH, CNM; Edwards, Digna R. Velez PhD; Andrews, Jeffrey C. MD; Woodworth, Alison L. PhD; Jerome, Rebecca N. MLIS, MPH; Fonnesbeck, Christopher J. PhD; McKoy, J. Nikki MPH; Hartmann, Katherine E. MD, PhD

Clinical ObGyn
Cochrane Reviews
Collapse Box

Abstract

OBJECTIVE: We systematically reviewed the effectiveness of progestogens for prevention of preterm birth among women with prior spontaneous preterm birth, multiple gestations, preterm labor, short cervix, or other indications.

DATA SOURCES: We searched MEDLINE and EMBASE databases for English language articles published from January 1966 to October 2011.

METHODS OF STUDY SELECTION: We excluded publications that were not randomized controlled trials or had fewer than 20 participants, identifying 34 publications, of which 19 contained data for Bayesian meta-analysis.

TABULATION, INTEGRATION, AND RESULTS: Two reviewers independently extracted data and assigned overall quality ratings based on predetermined criteria. Among women with prior preterm birth and a singleton pregnancy (five randomized controlled trials), progestogen treatment decreased the median risk of preterm birth by 22% (relative risk [RR] 0.78, 95% Bayesian credible interval 0.68–0.88) and neonatal death by 42% (RR 0.58, 95% Bayesian credible interval 0.27–0.98). The evidence suggests progestogen treatment does not prevent prematurity (RR 1.02, 95% Bayesian credible interval 0.87–1.17) or neonatal death (RR 1.44, 95% Bayesian credible interval 0.46–3.18) in multiple gestations. Limited evidence suggests progestogen treatment may prevent prematurity in women with preterm labor (RR 0.62, 95% Bayesian credible interval 0.47–0.79) and short cervix (RR 0.52, 95% Bayesian credible interval 0.36–0.70). Across indications, evidence about maternal, fetal, or neonatal health outcomes, other than reducing preterm birth and neonatal mortality, is inconsistent, insufficient, or absent.

CONCLUSION: Progestogens prevent preterm birth when used in singleton pregnancies for women with a prior preterm birth. In contrast, evidence suggests lack of effectiveness for multiple gestations. Evidence supporting all other uses is insufficient to guide clinical care. Overall, clinicians and patients lack longer-term information to understand whether intervention has the ultimately desired outcome of preventing morbidity and promoting normal childhood development.

© 2012 The American College of Obstetricians and Gynecologists

Login

Article Tools

Share